PP150 The Role Of Expert Consensus In UK Guidance: Patient Selection For Hydrogel Spacer Use During Prostate Cancer Radiotherapy

Introduction In UK males, prostate cancer is the most common cancer, with over 47,500 diagnosed annually. Radiotherapy a highly effective curative treatment but can be limited by dose to surrounding normal-tissues such as rectum. Radiation rectum reduced increasing distance between and hydrogel spacer. Despite National Institute of Health Care Excellence guidance, spacers are not widely funded in UK. Limited funding has necessitated patient prioritization, without any existing consensus on method. Studies have shown generally homogenous results reduction rectal toxicity across assessed subgroups, requirement prioritize remains. One way addressing appropriate use beneficial health technologies inclusion end-user experts decision-making. The study aim was identify among radiation oncologists prioritization for spacers. Methods We conducted Delphi where six leading clinical one urologist from experienced using participated two rounds online questionnaires virtual advisory board meetings. Results estimated that 83 percent patients who could potentially benefit spacer were denied access. Overall, ten points reached. Key ones concerning patient-access were: • Spacer eligible significantly reduces toxicity-related adverse events. Increased expected anticoagulation, diabetes inflammatory bowel disease. ultra-hypofractionated radiotherapy, radiotherapy modality key consideration selection. Patients should opportunity actively participate discussion regarding Conclusions Currently, all would access Consensus this indicates policy mechanisms warranted patients, provide equitable improving quality life.